Genmab A/S announced a partnership with Anthropic to embed Claude‑powered, agentic artificial intelligence into its research and development workflow. The collaboration will deploy Anthropic’s Claude for Life Sciences platform to streamline data processing, analysis, and document generation across Genmab’s clinical development priorities, while maintaining human oversight to satisfy regulatory requirements.
The partnership builds on Genmab’s existing AI initiatives, including a prior collaboration with OpenAI and the company’s “AI Everywhere” program that equips scientists with generative‑AI tools. By integrating Claude’s advanced natural‑language understanding and laboratory‑protocol comprehension, Genmab aims to reduce manual burden, accelerate decision‑making, and free researchers to focus on high‑value scientific questions.
Genmab’s executive team framed the deal as a key step in the company’s transition from a royalty‑collector to a fully integrated biotech. Tahamtan Ahmadi, Executive Vice President and Chief Medical Officer, said the partnership “will empower our teams to focus more time on high‑value scientific and strategic work, accelerating our path to patient impact.” The move is intended to scale Genmab’s R&D engine and enhance the efficiency of its clinical operations.
Anthropic’s Claude for Life Sciences platform has already been adopted by other major pharmaceutical companies such as Sanofi and AbbVie. Kate Jensen, Head of Americas at Anthropic, noted that the partnership “is designed to help Genmab focus on the hard problems that require human expertise and get therapies to patients faster.” The platform’s ability to understand laboratory protocols and integrate with scientific tools positions it as a powerful enabler for Genmab’s antibody programs.
Genmab reported strong revenue growth in the first half of 2025, and the AI partnership is part of a broader strategy to maintain a competitive advantage in antibody development. While the financial terms of the collaboration are undisclosed, the partnership signals Genmab’s commitment to leveraging cutting‑edge technology to accelerate its pipeline and improve operational efficiency.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.